Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Biomunex Pharmaceuticals SASStartup |
Active Organization Biomunex Pharmaceuticals SASStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | FR | Biomunex Pharmaceuticals SASStartup | 22 Mar 2024 |